AXIOMATIC-SSP

A Study of BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

AXIOMATIC-SSP: A Study of BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel 

Lead PI: Prof Graeme Hankey

Status: Recruiting

No. of Patients Currently Recruited: 165                               No. of Patients Required:  2350 

AXIOMATIC-SSP is a Phase 2, Randomised, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Convert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack. This trial aims to determine the safety and efficacy of adding different doses on an oral factor Xia inhibitor to dual antiplatelet therapy with aspirin and clopidogrel in 2350 patients with acute (<48 hours) minor ischaemic stroke or TIA.

Trial URL:

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=18554&isClinicalTrial=True